Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

ces with respect to the Company's clinical programs include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that preclinical data will indicate that urocortin 2 is not suitable for further clinical studies; risk that the CRF1 receptor antagonist candidate's Phase II proof of concept clinical studies will not support further clinical studies; and overall risk that the Company's clinical candidates will not proceed to later stage clinical trials. Risks associated with the Company's indiplon program include, but are not limited to, risk that indiplon approval and subsequent commercialization may be indefinitely delayed or never accomplished. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2007 and report on Form 10Q for the quarter ended June 30, 2008. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

NEUROCRINE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(in thousands, except for per share data)

Three Months Ended Nine Months Ended

September 30,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... China, notified,its shareholders today that the Annual ... 2007, has been postponed due the geographical,nature ... the mailing of,proxy materials. The Company is ...
... EDMONTON, Aug. 20 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), announced,today that it is ... bid,which will be conducted pursuant to the rules ... purchase up to 1,000,000 of its Class A ...
... ABUJA, August 20 The Chrome Group today announced ... of its companies on trading,platforms in Europe and the ... Group Chief Communications Officer, Mr. Val Oji said that ... Group was,implementing over the next two years. Chrome recently ...
Cached Biology Technology:Sinovac Announces Postponement of Annual General Meeting 2BioMS Medical announces its intention to renew a normal course issuer bid 2Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4
(Date:4/21/2014)... can help treat and prevent influenza and respiratory ... the lungs and breathing passages, according to research ... new Institute for Biomedical Sciences. , In a ... upcoming publication of the International Journal of Molecular ... ginseng, a well-known herbal medicine, on human health. ...
(Date:4/21/2014)... Like a daily pill to lower cholesterol can reduce ... reduces eye inflammation could help save the vision of ... already targeted with high doses of niacin to decrease ... also be an effective mark for these patients, said ... Georgia at Georgia Regents University. , Martin is ...
(Date:4/21/2014)... domesticated chili pepper now the world,s most ... team of researchers, led by a plant scientist ... from the four-pronged investigation based on linguistic ... traditional archaeological and genetic data suggest a ... the domesticated chili pepper. That region, extending from ...
Breaking Biology News(10 mins):Ginseng can treat and prevent influenza and RSV, researcher finds 2Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Birthplace of the domesticated chili pepper identified in Mexico 2
... Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link ... blood. In the long term, the research may well help ... been published in the Journal of the American College ... which the opening of the aortic valve is narrowed ...
... PULLMAN, Wash. A class of drugs used to treat ... treating cancers and immune-related diseases, a new WSU-led study has ... have a major impact on its ability to affect specific ... "This was rather unexpected, given how relatively simple the molecules ...
... iPhone users now have access to a free ... including electricity, natural gas, biodiesel, e85 Ethanol, propane ... Energy Laboratory (NREL) developed the new mobile application ... local stakeholders across the country in an effort ...
Cached Biology News:Danish researchers predict risk of valvular heart disease 2Researcher finds potential new use for old drugs 2NREL developed mobile app for alternative fueling station locations released 2
... Immunogen: Synthetic peptide derived from the C ... protein This peptide sequence is downstream ... Zymed polyclonal Connexin 36 antibody Cat. No. ... 36. Reactivity: Mouse (positive control: mouse ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: